Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344094 · ClinicalTrials.gov registry record
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 30
- Enrollment target
NCT03344094: Completed study, sponsored by University of Chicago.
NCT03344094 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03344094 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
Primary Outcome
measured through lymphocyte surface marker stains, from patients, before and after ocrelizumab (Ocrevus) therapy Mononuclear cells (MNC) will be stained, for flow cytometry, with marker antibodies to B cells. The change in the percentage of each subset will be compared before and after treatment with paired t tests and ANOVA.
Interventions
- DRUG ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2019-04-10 |
What the finished NCT03344094 record still lists
NCT03344094 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ocrelizumab is the first listed.
NCT03344094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03344094 about?
NCT03344094 is a clinical study titled "Mechanism of Action of Ocrelizumab in Multiple Sclerosis". Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
What is the current status of trial NCT03344094?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-02-23. Estimated completion is 2019-04-10.
What interventions are being tested in trial NCT03344094?
The interventions under investigation include: ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03344094?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI